thrombocytopenia 3
MONDO:0010120
An inherited thrombocytopenia caused by a variation in the FYB1 gene, characterized by small-platelet thrombocytopenia beginning in infancy, with variable mucocutaneous bleeding including petechiae, epistaxis, and heavy menstrual bleeding. Platelet studies in affected individuals reveal reduced pseudopodia formation, impaired integrin activation, increased basal P-selectin and PAC-1 expression, and reduced ability to upregulate activation markers following ADP stimulation. Megakaryocyte abnormalities, including reduced numbers of mature multilobulated megakaryocytes and impaired proplatelet development, reflect a defect in cytoskeletal organization linked to the loss of FYB1's adaptor function in integrin-mediated signaling.
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
MONDO disease family
Recruiting studies by city
Trial status
Trial phase
Study start year
Investigated drug interventions
Drugs being studied
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.